pan-TOE-pra-zole 
Unlabeled Use:
Contraindicated in:
Use Cautiously in:
Derm: ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS, cutaneous lupus erythematosus, DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS.
Endo: hyperglycemia.
F and E: hypocalcemia (especially if treatment duration ≥3 mo), hypokalemia (especially if treatment duration ≥3 mo), hypomagnesemia (especially if treatment duration ≥3 mo).
GI: abdominal pain, CLOSTRIDIOIDES DIFFICILE-ASSOCIATED DIARRHEA (CDAD), diarrhea, eructation, flatulence, fundic gland polyps.
GU: acute tubulointerstitial nephritis.
Hemat: vitamin B12 deficiency.
MS: bone fracture.
Neuro: headache.
Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS, ANGIOEDEMA, OR TUBULOINTERSTITIAL NEPHRITIS, systemic lupus erythematosis.
Drug-Drug:
(Generic available)
Gastroesophageal Reflux Disease
Gastric Hypersecretory Conditions
Absorption: Tablet is enteric-coated; absorption occurs only after tablet leaves the stomach.
Distribution: Unknown.
Protein Binding: 98%.
Metabolism/Excretion: Primarily metabolized by the CYP2C19 and CYP3A4 isoenzymes in the liver; the CYP2C19 isoenzyme exhibits genetic polymorphism (15–20% of Asian patients and 3–5% of Caucasian and Black patients may be poor metabolizers and may have significantly ↑ pantoprazole concentrations and an ↑ risk of adverse effects); inactive metabolites are excreted in urine (71%) and feces (18%).
Half-life: 1 hr.
(effect on acid secretion)
| ROUTE | ONSET† | PEAK | DURATION† |
|---|---|---|---|
| PO | 2.5 hr | unknown | 1 wk |
| IV | 15–30 min | 2 hr | unknown |
†Onset = 51% inhibition; duration = return to normal following discontinuation.
NDC Code*